Novo Nordisk A/S Common Stock (NVO)

Semaglutide was no better than a placebo.

Stocks were up sharply to start the holiday week.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

The company said that it is discontinuing the trials.

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.

November is a great month to be thankful for opportunities to invest in these fantastic companies.

Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity.

The management team conducted a cost-cutting effort that is likely to result in a more efficient business.

Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.

KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a previous $12.00. This downgrade reflects growing concerns over the telehealth company's financial performance, operational efficiency, and competitive landscape. The immediate

Novo Nordisk just addressed a problem that has prevented some from taking these drugs.

European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial markets. While the general trend has seen some recent slips, the pharmaceutical sector, a traditionally defensive industry, has demonstrated a mixed performance, showcasing both

Novo Nordisk is investing aggressively to improve its pipeline of drugs in development.

Indianapolis, IN – November 19, 2025 – Eli Lilly and Company (NYSE: LLY), the pharmaceutical titan, finds itself at the epicenter of market speculation, firmly placed on "stock split watch" as its share price has soared past the formidable $1,000 mark. This extraordinary ascent, fueled by groundbreaking drug innovations and robust

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.

The market is hopping with interesting news.

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.

Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this year, and continuing to teeter on the edge after relisting on the Nasdaq.